Teva enters Tuznue license agreement with Prestige Biopharma

Teva (TEVA) entered into a license agreement with Prestige Biopharma, for the commercialization of Tuznue, a biosimilar to Herceptin, across a majority of European markets. Tuznue is approved for the treatment of breast cancer and metastatic gastric cancer. Prestige Biopharma received the European Commission marketing authorization for Tuznue in September 2024. Under the terms of the license and supply agreement, Teva secured rights to market and distribute Tuznue in a majority of European markets. Prestige Biopharma will be responsible for production and supply through its EU-GMP-certified, high-tech facilities equipped with advanced single-use technology.